

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Perry Jennifer Scott</u> (Last) (First) (Middle) <u>C/O BICYCLE THERAPEUTICS PLC</u> <u>BLOCKS A & B, PORTWAY BUILDING</u> (Street) <u>CAMBRIDGE X0 CB21 6GS</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/17/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>BICYCLE THERAPEUTICS PLC [BCYC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Operating Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽¹⁾	93,872 ⁽²⁾	D	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	(3)	09/01/2032	Ordinary Shares	20,000	26.45	D	
Employee Stock Option (right to buy)	(4)	01/03/2033	Ordinary Shares	3,576	29.6	D	
Employee Stock Option (right to buy)	(5)	03/13/2033	Ordinary Shares	30,000	20.02	D	
Employee Stock Option (right to buy)	(6)	01/02/2034	Ordinary Shares	31,000	18.08	D	
Employee Stock Option (right to buy)	(7)	07/16/2034	Ordinary Shares	58,000	22.6	D	
Employee Stock Option (right to buy)	(8)	01/02/2035	Ordinary Shares	87,000	14	D	
Employee Stock Option (right to buy)	(9)	01/02/2036	Ordinary Shares	100,000	7.08	D	

Explanation of Responses:

- The Ordinary Shares may be represented by American Depositary Shares, each of which represents one ordinary share.
- Includes 84,697 restricted share units ("RSUs"). 447 RSUs vest in four equal quarterly installments commencing on April 3, 2026; 8,000 RSUs vest in eight equal quarterly installments commencing on April 2, 2026; 26,250 RSUs vest in twelve equal quarterly installments commencing on April 2, 2026; and 50,000 RSUs vest one-fourth (1/4) on January 2, 2027 and the remaining RSUs vest in twelve equal quarterly installments thereafter.
- This option vested with respect to one-fourth (1/4) of the total number of shares underlying the option on August 24, 2023 and the remaining shares vested or vest in 36 equal monthly installments thereafter.
- This option vested with respect to one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares vested or vest in 36 equal monthly installments thereafter.
- This option vested with respect to one-fourth (1/4) of the total number of shares underlying the option on March 13, 2024 and the remaining shares vested or vest in 36 equal monthly installments thereafter.

monthly installments thereafter.

6. This option vested with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares vested or vest in 36 equal monthly installments thereafter.

7. This option vested with respect to one-fourth (1/4) of the total number of shares underlying the option on July 16, 2025 and the remaining shares vested or vest in 36 equal monthly installments thereafter.

8. This option vested with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares vested or vest in 36 equal monthly installments thereafter.

9. This option vests with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares vest in 36 equal monthly installments thereafter.

/s/ Travis Thompson,
Attorney-in-Fact

03/25/2026

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Forms 3, 4, and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints each of Hayden Ziebel-Lipitz, Travis Thompson and Zafar Qadir of Bicycle Therapeutics plc (the "**Company**"), signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

(1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "**SEC**") Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), and the rules thereunder in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 (including amendments thereto) and timely file such forms with the SEC and any stock exchange or any similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorneyinfect full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneyinfect, or such attorneyinfect's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: 17 March 2026

/s/ Jennifer Perry

Name: Jennifer Perry